This study suggests that PRA and PRB play distinct roles in regulating the behavior of FE25 cells (a pre-ovarian cancer cell line) and that targeting these receptors could be a potential therapeutic strategy for OC treatment. This evidence concerns the gene S100A6 and ovarian carcinoma.